Home › Blood Disorders › New Jersey › Clifton
Blood Disorders clinical trials in Clifton, NJ
3 studies for Blood Disorders are looking for participants at sites in and around Clifton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack · 7 mi away
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- John Theurer Cancer Center / Hackensack University, Hackensack · 7 mi away
About Blood Disorders
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
More about Blood Disorders on MedlinePlus
Blood Disorders trials in other cities
- Boston, MA10 studies
- Atlanta, GA10 studies
- Houston, TX9 studies
- Los Angeles, CA9 studies
- The Bronx, NY8 studies
- New York City, NY7 studies
- Nashville, TN7 studies
- Mountain View, CA6 studies
- Durham, NC5 studies
- Washington, DC5 studies
- Greenville, NC5 studies
- Portland, OR5 studies
Other studies in Clifton
- Non-Small Cell Lung Cancer24 studies
- Cancer (all types)15 studies
- Multiple Myeloma14 studies
- Metastatic Cancer12 studies
- Acute Myeloid Leukemia12 studies
- Prostate Cancer12 studies
- Breast Cancer12 studies
- Ovarian Cancer11 studies
- Lung Cancer10 studies
- Endometrial Cancer8 studies
- Triple-Negative Breast Cancer8 studies
- Colorectal Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.